Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
FBI issues safety warning about counterfeit versions of weight loss drug semaglutide
Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
JD Supra1d
FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers
Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
The GLP-1 shortages are over. What happens next?
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...
Medscape2d
The End of Compounded GLP-1s: What Physicians Need to Know
FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...
FDA update could extend Hims & Hers’ compounding timeline, says BofA
BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...
Fierce Pharma8d
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
‘Don’t Buy the Dip,’ Says Morgan Stanley About Hims & Hers Stock
Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...